Medically reviewed by Dr. Tom Biernacki, DPM
Board-certified podiatric surgeon | Balance Foot & Ankle, Howell & Bloomfield Hills, MI
Last reviewed: May 2026
Choosing the right Toenail Fungus Treatment: Ranked by Evidence () depends on one clinical variable our podiatrists assess before any product recommendation — and most online comparisons never mention it. Getting this wrong is the most common reason patients cycle through multiple products without relief. Call (810) 206-1402 — expert podiatric care across Michigan.

| Treatment | Mycological Cure Rate | Complete Cure Rate | Course Length | Best For |
|---|---|---|---|---|
| Terbinafine oral (Lamisil) — generic | 70–80% | 38–59% | 12 weeks | Dermatophyte onychomycosis (T. rubrum); most cases |
| Itraconazole oral (pulse dosing) | 54–70% | 35–50% | 3 monthly pulses | When terbinafine not tolerated; broader spectrum (Candida) |
| Fluconazole oral (weekly) | 48–62% | 25–40% | 6–12 months | Candida onychomycosis; terbinafine intolerance |
| Efinaconazole topical (Jublia 10%) | 55% | 18% | 48 weeks daily | Mild–moderate; liver disease; drug interactions; patient preference |
| Tavaborole topical (Kerydin 5%) | 31–36% | 7% | 48 weeks daily | Limited nail involvement; cannot take oral |
| Ciclopirox topical (Penlac 8%) | 29–36% | 5–8% | 48 weeks daily | Early/superficial infections; adjunct to oral |
| Laser treatment (Nd:YAG 1064nm) | 30–60% | Variable | 3–4 sessions | Oral contraindicated; adjunct for refractory cases |
| Combination oral + topical | Higher than either alone | Higher | Per component | Severe disease; previous treatment failure; diabetic patients |
| Patient Profile | Best Treatment Choice | Why |
|---|---|---|
| Healthy adult; confirmed dermatophyte; 1–3 nails; <50% involvement | Oral terbinafine 250mg x 12 weeks | Highest cure rate; shortest course; inexpensive generic; well-tolerated |
| Confirmed dermatophyte; >50% involvement; thickened nails | Oral terbinafine + topical efinaconazole | Combination improves outcomes for extensive disease |
| Liver disease or significant drug interactions (e.g., warfarin, cyclosporine) | Topical efinaconazole (Jublia) 48 weeks | No systemic absorption; no liver metabolism; no drug interactions |
| Fingernail involvement or Candida onychomycosis | Oral itraconazole pulse x 3 or fluconazole weekly | Better Candida coverage than terbinafine; fingernails respond faster |
| Previous oral antifungal failure; severe or refractory disease | Repeat oral (confirm culture) + laser adjunct | Culture identifies resistant species or misdiagnosis; laser adds non-pharmacologic pressure |
| Mild superficial white onychomycosis only | Topical ciclopirox or efinaconazole | Surface-only infection most topical-accessible; oral may be avoided |
| Diabetic patient; multiple nails; high infection risk | Oral terbinafine + meticulous foot hygiene + podiatric monitoring | High infection risk warrants effective oral treatment; podiatric supervision for wound prevention |
Choosing the Best Toenail Fungus Treatment
The “best” toenail fungus treatment depends on the extent of infection, the causative organism, the patient’s health status and medications, and whether topical vs. oral therapy is appropriate. One answer applies to most patients with confirmed dermatophyte toenail fungus: oral terbinafine (generic Lamisil) is the most effective available treatment with the strongest clinical evidence, the highest cure rates, the shortest treatment course, and the lowest cost.
No products found.
Oral Terbinafine (Lamisil): Why It’s the Gold Standard
Oral terbinafine (brand name Lamisil; widely available as generic) is an allylamine antifungal that works by inhibiting squalene epoxidase, an enzyme in the fungal sterol synthesis pathway, causing accumulation of toxic squalene that kills the fungus. It achieves nail concentrations via the bloodstream and nail matrix, bypassing the nail penetration problem that limits topical agents. The standard course is 250mg daily for 12 weeks for toenail infections. Cure rates from multiple randomized controlled trials: mycological cure (lab evidence the fungus is gone) 70–80%; complete cure (clear nail + negative culture) 38–59%. The remaining patients who are mycologically cured but don’t achieve complete nail clearance have often killed the fungus but are waiting for the nail to fully grow out — which takes 12–18 months after the drug is stopped.
Terbinafine is generally well-tolerated. The most common side effects are GI (nausea, diarrhea, abdominal discomfort) in 5–10% of patients, and taste disturbances in 2–3% — an unusual but distinctive side effect (metallic taste; altered or diminished taste sensation) that resolves after stopping the medication. Rare hepatotoxicity (liver injury) has been reported; routine liver function tests are not required in healthy patients taking a 12-week course, but patients with pre-existing liver disease should use a different treatment. Terbinafine interacts with CYP2D6 substrates (some antidepressants, beta-blockers, antipsychotics) — a medication review before prescribing is important.
Prescription Topicals: When Oral Isn’t an Option
FDA-approved prescription topical antifungals are an important option for patients who cannot take oral antifungals (due to liver disease, drug interactions, or patient preference). Efinaconazole (Jublia 10%) was specifically engineered with low nail binding affinity to achieve high transungual penetration — and is the most effective topical with mycological cure rates of approximately 55% at 48 weeks of daily application. It is pregnancy category C and has no significant drug interactions. It is applied once daily to the entire affected nail and 5mm of surrounding skin. Tavaborole (Kerydin 5%) has lower cure rates (31–36%) but uses a boron-containing molecule with different penetration chemistry. Ciclopirox (Penlac 8%) is the oldest prescription topical with the lowest cure rates (29–36%) but some evidence as an oral adjunct. All topicals require consistent daily application for 48 weeks — adherence is the major practical challenge.
Why Treatment “Fails”: The Most Common Reasons
Toenail fungus treatment frequently appears to fail for predictable, preventable reasons. The most common: treating without confirming the diagnosis. Approximately 50% of nail dystrophy (abnormal-looking nails) is not fungal — it’s nail psoriasis, trauma, lichen planus, or other non-infectious causes that won’t respond to any antifungal. Nail culture or KOH testing before treatment is the single most important step to avoid months of ineffective treatment. The second most common reason: shoe reservoir re-infection. Old shoes harbor live dermatophyte spores for months and re-infect treated nails. After completing treatment, replace or decontaminate heavily-worn footwear. Third: untreated concurrent tinea pedis (athlete’s foot) on the surrounding skin provides a continuous source of fungal re-seeding to the nails.
At Balance Foot & Ankle, Dr. Tom Biernacki and Dr. Carl Jay provide in-office nail culture, KOH testing, prescription antifungal treatment, and laser therapy for toenail fungus at both the Howell and Bloomfield Hills offices. Call (810) 206-1402.
American Academy of Dermatology: Nail Fungus
Ready to Get Relief?
Same-day appointments available in Howell & Bloomfield Hills, MI
4.9★ | 1,123 Reviews | 3,000+ Surgeries
Or call: (810) 206-1402
For a complete clinical overview: Toenail Fungus Complete Treatment Guide — oral, topical, laser and home remedy evidence reviewed
Dr. Tom Biernacki, DPM is a double board-certified podiatrist and foot & ankle surgeon at Balance Foot & Ankle Specialists in Southeast Michigan. With over a decade of clinical experience, he specializes in heel pain, bunions, diabetic foot care, sports injuries, and minimally invasive surgery. Dr. Biernacki is a member of the APMA and ACFAS, and his patient education content on MichiganFootDoctors.com and YouTube has reached over one million views.